NCT05582850View on ClinicalTrials.gov

DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

April 8, 2025

Study Completion Date

July 28, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

DT-9081 - dose escalation

Patients will be dosed orally once daily. The schedule might be adjusted in case of toxicities.

DRUG

DT-9081 - expansion

A homogeneous patient population will receive DT-9081 at up to 3 dose levels.

Trial Locations (4)

Unknown

Institut Jules Bordet, Anderlecht

Université Catholique de Louvain, Leuven

Institut Curie, Paris

Institut Claudius Regaud, Toulouse

Sponsors
All Listed Sponsors
lead

Domain Therapeutics SA

INDUSTRY